Genetic testing not cost-effective in guiding initial dosing of common blood thinner

New analyses led by the University of Cincinnati (UC) show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news151608661.html">Genetic testing not cost-effective in guiding initial dosing of common blood thinner</a></p> <p>New analyses led by the University of Cincinnati (UC) show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding.</p>